Further than NASH: NASH & Wider Fibrosis Seminar - Seminar A

Next Steps: Uptake of Drugs to Market Seminar - Seminar B

Overlap and relationships across organ-specific pathological fibrosis, as well as lessons learned from other fibrotic disease clinical drug development and regulatory intelligence.

Chaired by: Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer

 

9.00 Opening Remarks
Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer

 

9.15 The Importance of Epigenetic Changes in the Pathogenesis of NASH & Fibrosis

Glenn Rosen, Vice President, Preclinical Translational Sciences & Small Molecules, Coherus
Biosciences

 

9.45 Fibrosis & Inflammation: Approaches for Targeting

Rugmani Padmanabhan Iyer, Senior Scientist – Cardiovascular, Inflammation & Fibrosis,
Merck

 

10.15 Morning Break & Networking 

 

11.00 Keeping up with the Joneses: What Can we Learn From Pulmonary & Cardiac Fibrosis?

Lee Borthwick, Fibrosis Biology Lecturer, Newcastle University

11.30 Effect of Iron on Fibrosis in the Heart 

Claudio Mori, Medical Strategy & Portfolio Lead,  Vifor Pharma 

 

12.00 Lunch & Networking

 

1.00 Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis

Rusty Montgomery, Director, Research, Miragen Therapeutics

 

1.30 CORMs: A Single NASH Therapeutic Treating Inflammation, Fibrosis & Metabolic
Stress

Jeffrey Wager, Chairman & Chief Executive Officer, Proterris

 

2.00 Lessons Learned from Antifibrotic Trials in NASH & Where do we go From Here?

Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

 

2.30 Concluding Panel Discussion: Challenges in Anti-Fibrotic Drug Development;
Why a Paradigm Shift is Needed

Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer
Glenn Rosen, Vice President – Preclinical Translational Sciences & Small Molecules,
Coherus Biosciences
Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

 

 

Understanding key considerations from pharma and payers, & evaluating consequences of change to market opportunity and access for NASH

Chaired by: Yasmeen Rahimi, Co-Head of Biotechnology Research, Managing Director, Senior Research Analyst, Roth Capital Partners

 

9.00 Opening Remarks
Chaired by: Yasmeen Rahimi, Co-Head of Biotechnology Research, Managing Director,
Senior Research Analyst, Roth Capital Partners

 

9.15 Consideration & Decision Making Process of Payers for NASH Including Opinions
on Surrogate Endpoints & the Need to Biopsy or Not

Derek Achila, Director & Senior Analyst – Biotechnology, Stifel Nicolaus

 

9.45 Potential Impact & Value of NASH Therapeutics

Jagpreet Chhatwal, Assistant Professor, Harvard Medical School

 

10.15 Morning Break & Networking 

 

11.00 Panel Discussion: How do we Bring Strategies to a Wider Population?

Derek Achila, Director & Senior Analyst – Biotechnology, Stifel Nicolaus

Jagpreet Chhatwal, Assistant Professor, Harvard Medical School

Yasmeen Rahimi, Co-Head of Biotechnology Research Managing Director, Senior
Research Analyst, Roth Capital Partners

 

12.00 Lunch & Networking 

 

1.00 NASH Market in China

Ankang Li, Chief Financial Officer, Terns Pharmaceuticals

 

1.30 - 2.30 Payer's Roundtable Discussions

These practical and highly interactive breakout roundtables are an opportunity for cross-stakeholder attendees to crowd-source solutions and share opinions around key challenges in market access.

A uniquely valuable chance for attendees to unite around hot topics, debate best practice and share experience to identify solutions. Gain candid insights you can take back to the office from your counterparts across industry. 

1.30-1.45 Introduction to Topics
1.45 - 2.15 Roundtable Discussion
2.15-2.30 Feedback Panel: Sharing insights from across tables and topics

Topics to include:

  • Is the market opportunity only with F4 patients?
  • How will the patient journey change once there is an available therapy? Under what rules and technology will the journey be redefined?
  • Outside of the clinical trial context, how do non-invasive biomarkers fit into the diagnostic & management algorithm for NASH patients?
  • What are the economics of NASH with a commercially available product? Does this have a knock-on effects for new companies starting to address NASH?

 

For all details on each session, please download the full event guide.